Pharmacogenomics variants are associated with BMI differences between individuals with bipolar and other psychiatric disorders

References

• 1. Lopresti AL, Drummond PD. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 92–99 (2013).
  Medline CASGoogle Scholar
• 2. Engelke C, Lange-Asschenfeldt C, Peter S et al. A cross-continental analysis of weight gain, psychiatric diagnoses and medication use during inpatient psychiatric treatment. The international study on physical illness in mentally ill. Eur. Psychiatry 48(1), 65–70 (2018).
  MedlineGoogle Scholar
• 3. Bahrami S, Eiel Steen N, Shadrin A et al. Shared genetic loci between body mass index and major psychiatric disorders: a genome-wide association study. JAMA Psychiatry 77(5), 503–512 (2020).
  MedlineGoogle Scholar
• 4. Gurusamy J, Gandhi S. Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: a systematic review. Asian J. Psychiatr. 36, 73–85 (2018).
  MedlineGoogle Scholar
• 5. Kouidrat Y, Amad A, Stubbs B et al. Disordered eating behaviors as a potential obesogenic factor in schizophrenia. Psychiatry Res. 269, 450–454 (2018).
  MedlineGoogle Scholar
• 6. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. Annu Rev. Sociol. 36, 349–370 (2010).
  MedlineGoogle Scholar
• 7. Mezquida G, Savulich G, Garcia-Rizo C et al. Inverse association between negative symptoms and body mass index in chronic schizophrenia. Schizophr. Res. 192, 69–74 (2018).
  Medline CASGoogle Scholar
• 8. McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J. Clin. Psychiatry 63(3), 207–213 (2002).
  MedlineGoogle Scholar
• 9. Bond DJ, Andreazza AC, Hughes J et al. A longitudinal study of the relationships between mood symptoms, body mass index, and serum adipokines in bipolar disorder. J. Clin. Psychiatry 78(4), 441–448 (2017).
  MedlineGoogle Scholar
• 10. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ 361, k1951 (2018).
  MedlineGoogle Scholar
• 11. Jantaratnotai N, Mosikanon K, Lee Y, McIntyre RS. The interface of depression and obesity. Obes. Res. Clin. Pract. 11(1), 1–10 (2017).
  MedlineGoogle Scholar
• 12. Altall RM, Qusti SY, Filimban N. SLC22A1 And ATM genes polymorphisms are associated with the risk of Type 2 diabetes mellitus in western Saudi Arabia: a case–control study. Appl. Clin. Genet. 12, 213 (2019).
  Medline CASGoogle Scholar
• 13. Clarke TK, Hall LS, Fernandez-Pujals AM et al. Major depressive disorder and current psychological distress moderate the effect of polygenic risk for obesity on body mass index. Transl. Psychiatry 5(5), e592 (2015).
  MedlineGoogle Scholar
• 14. Zhang JP, Lencz T, Zhang RX et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr. Bull. 42(42), 1418–1437 (2016).
  MedlineGoogle Scholar
• 15. Santos-Júnior AD, Henriques TB, Palandi de Mello M et al. Corrigendum to ‘pharmacogenetics of risperidone and cardiovascular risk in children and adolescents’. Int. J. Endocrinol. 2017, 8165368 (2017).
  MedlineGoogle Scholar
• 16. Piatkov I, Caetano D, Assur Y et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers. Med. 10, 235 (2017).
  Medline CASGoogle Scholar
• 17. Ninomiya-Baba M, Matsuo J, Sasayama D et al. Association of body mass index-related single nucleotide polymorphisms with psychiatric disease and memory performance in a Japanese population. Acta Neuropsychiatr. 29(5), 299–308 (2017).
  MedlineGoogle Scholar
• 18. Pierce CA, Block RA, Aguinis H. Cautionary note on reporting eta-squared values from multifactor ANOVA designs. Educ. Psychol. Meas. 64(6), 916–924 (2004).
  Google Scholar
• 19. Vendelbo J, Olesen RH, Lauridsen JK et al. Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African–Americans than Caucasians. Pharmacogenomics J. 18(18), 121–126 (2018).
  Medline CASGoogle Scholar
• 20. Ichihara S, Yamada Y, Kato K et al. Association of a polymorphism of ABCB1 with obesity in Japanese individuals. Genomics 91(91), 512–516 (2008).
  Medline CASGoogle Scholar
• 21. Yang X, Yan Y, Fang S et al. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms. Medicine 98(12), e14908 (2019).
  Medline CASGoogle Scholar
• 22. Acalovschi M, Tirziu S, Chiorean E, Krawczyk M, Grünhage F, Lammert F. Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids 44(44), 521–526 (2009).
  Medline CASGoogle Scholar
• 23. Huffman JE, Albrecht E, Teumer A et al. Modulation of genetic associations with serum urate levels by body-mass-index in humans. PLoS ONE 10(3), e0119752 (2015).
  MedlineGoogle Scholar
• 24. Domjanović IK, Lovrić M, Trkulja V et al. Interaction between ABCG2 421C >A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br. J. Clin. Pharmacol. 84(84), 2106–2119 (2018).
  MedlineGoogle Scholar
• 25. Horváthová V, Bohatá J, Pavlíková M et al. Interaction of the p. Q141K Variant of the ABCG2 gene with clinical data and cytokine levels in primary hyperuricemia and gout. J. Clin. Med. 8(11), 1965 (2019).
  CASGoogle Scholar
• 26. Roberts RL, Wallace MC, Phipps-Green AJ et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 17(17), 201–203 (2017).
  Medline CASGoogle Scholar
• 27. Bailón-Soto CE, Galaviz-Hernández C, Lazalde-Ramos BP et al. Influence of CYP1A1* 2C on high triglyceride levels in female Mexican indigenous Tarahumaras. Arch. Med. Res. 45(45), 409–416 (2014).
  Medline CASGoogle Scholar
• 28. Crandall CJ, Sehl ME, Crawford SL et al. Sex steroid metabolism polymorphisms and mammographic density in pre-and early perimenopausal women. Breast Cancer Res. 11(4), R51 (2009).
  MedlineGoogle Scholar
• 29. Jarvis MD, Palmer BR, Pilbrow AP et al. CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients. Clin. Exp. Pharmacol. Physiol. 37(2), 193–198 (2010).
  Medline CASGoogle Scholar
• 30. Kocabaş N, Şardaş S, Cholerton S, Daly AK, Karakaya AE. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Arch. Toxicol. 76(76), 643–649 (2002).
  Medline CASGoogle Scholar
• 31. Vasudev K, Choi Y, Norman R, Kim RB, Schwarz UI. H. Genetic determinants of clozapine-induced metabolic side effects. Can. J. Psychiatry 62(2), 138–149 (2017).
  MedlineGoogle Scholar
• 32. Cardoso J, Abrão MS, Berardo PT et al. Role of cytochrome P450 2C19 polymorphisms and body mass index in endometriosis: a case–control study. Eur. J. Obstet. Gynecol. Reprod. Biol. 219, 119–123 (2017).
  Medline CASGoogle Scholar
• 33. Nussbaum LA, Dumitraşcu V, Tudor A, Grădinaru R, Andreescu N, Puiu M. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom. J. Morphol. Embryol. 55(55), 877–884 (2014).
  MedlineGoogle Scholar
• 34. Costa-Urrutia P, Colistro V, Jiménez-Osorio AS et al. Genome-wide association study of body mass index and body fat in Mexican-Mestizo Children. Genes 10(11), 945 (2019).
  CASGoogle Scholar
• 35. Wang CP, Hung WC, Yu TH et al. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset Type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp. Clin. Endocrinol. Diabetes 118(118), 346–352 (2010).
  Medline CASGoogle Scholar
• 36. Paulzen M, Haen E, Stegmann B et al. Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone, a pharmacokinetics-based hypothesis. Psychoneuroendocrinology 73, 9–15 (2016).
  Medline CASGoogle Scholar
• 37. Reddy KR, Deepika ML, Supriya K et al. CYP11A1 microsatellite (tttta) n polymorphism in PCOS women from South India. J. Assist. Reprod. Genet. 31(31), 857–863 (2014).
  MedlineGoogle Scholar
• 38. Wang Y, Wu X, Cao Y, Yi L, Chen J. A microsatellite polymorphism (tttta) n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome. Fertil. Steril. 86(86), 223–226 (2006).
  Medline CASGoogle Scholar
• 39. Yan H, Guo Y, Yang TL, Zhao LJ, Deng HW. A family-based association study identified CYP17 as a candidate gene for obesity susceptibility in Caucasians. Genet. Mol. Res. 11(11), 1967 (2012).
  Medline CASGoogle Scholar
• 40. Olson SH, Orlow I, Bayuga S. Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control 19(19), 955–963 (2008).
  MedlineGoogle Scholar
• 41. Yousefi M, Karmaus W, Mudd LM et al. Expression of CYP19 and CYP17 is associated with leg length, weight, and BMI. Obesity 19(2), 436–441 (2011).
  Medline CASGoogle Scholar
• 42. Long JR, Shu XO, Cai Q et al. CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int. J. Obes. (Lond). 31(31), 418–423 (2007).
  Medline CASGoogle Scholar
• 43. Morandi A, Zusi C, Corradi M et al. Minor diplotypes of FMO3 might protect children and adolescents from obesity and insulin resistance. Int. J. Obes. (Lond). 42(42), 1243–1248 (2018).
  Medline CASGoogle Scholar
• 44. Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Alfredo Martinez J. MENA Project. Association of methylation signatures at hepatocellular carcinoma pathway genes with adiposity and insulin resistance phenotypes. Nutr. Cancer 71(5), 840–851 (2019).
  Medline CASGoogle Scholar
• 45. Almoshabek HA, Mustafa M, Al-Asmari MM, Alajmi TK, Al-Asmari AK. Association of glutathione S-transferase GSTM1 and GSTT1 deletion polymorphisms with obesity and their relationship with body mass index, lipoprotein and hypertension among young age Saudis. JRSM Cardiovasc. Dis. 5, 2048004016669645 (2016).
  Google Scholar
• 46. Villamil-Ramírez H, León-Mimila P, Macias-Kauffer LR et al. A combined linkage and association strategy identifies a variant near the GSTP1 gene associated with BMI in the Mexican population. J. Hum. Genet. 62(62), 413–418 (2017).
  Medline CASGoogle Scholar
• 47. Pašalić D, Marinković N. Genetic polymorphisms of the CYP1A1, GSTM1, and GSTT1 enzymes and their influence on cardiovascular risk and lipid profile in people who live near a natural gas plant. Arh. Hig. Rada Toksikol. 68(68), 46–52 (2017).
  Medline CASGoogle Scholar
• 48. Knowles JW, Xie W, Zhang Z et al. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J. Clin. Invest. 125(125), 1739–1751 (2015).
  MedlineGoogle Scholar
• 49. Huan T, Liu C, Joehanes R et al. A systematic heritability analysis of the human whole blood transcriptome. Hum. Genet. 134(134), 343–358 (2015).
  Medline CASGoogle Scholar
• 50. Amer MA, Ghattas MH, Abo-Elmatty DM, Abou-El-Ela SH. Evaluation of glutathione S-transferase P1 genetic variants affecting Type-2 diabetes susceptibility and glycemic control. AMS 8(4), 631 (2012).
  CASGoogle Scholar
• 51. Rodrigues C, Costa E, Vieir E. Bilirubin dependence on UGT1A1 polymorphisms, hemoglobin, fasting time and body mass index. Am. J. Med. Sci. 343(343), 114–118 (2012).
  MedlineGoogle Scholar
• 52. Rougée LR, Miyagi SJ, Collier AC. Obstetric obesity is associated with neonatal hyperbilirubinemia with high prevalence in native Hawaiians and Pacific Island women. Hawaii J. Med. Public Health. 75(75), 373 (2016).
  MedlineGoogle Scholar
• 53. Shafiu M, Johnson RJ, Turner ST et al. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press. Res. 35(35), 477–482 (2012).
  Medline CASGoogle Scholar
• 54. Tarasova L, Kalnina I, Geldnere K et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated Type 2 diabetes patients. Pharmacogenet. Genomics 22(22), 659–666 (2012).
  Medline CASGoogle Scholar
• 55. Sandvik P, Lydersen S, Hegstad S, Spigset O. Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa. Pharmacol Res Perspect. 8(3), e00615 (2020).
  Medline CASGoogle Scholar
• 56. Hosono S, Matsuo K, Ito H et al. Interaction between CYP19A1 polymorphisms and body mass index in the risk of endometrial cancer in postmenopausal Japanese women. Asian Pac. J. Cancer Prev. 12, 2747–2752 (2011).
  MedlineGoogle Scholar
• 57. Rahmioglu N, Heaton J, Clement G et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet. Genomics 21(21), 642–651 (2011).
  Medline CASGoogle Scholar
• 58. Ruaño G, Villagra D, Szarek B et al. Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomark. Med. 5(5), 439–449 (2011).
  CASGoogle Scholar
• 59. Friedrichsen M, Poulsen P, Wojtaszewski J, Hansen PR, Vaag A, Rasmussen HB. Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function. PLoS ONE 8(2), e56861 (2013).
  Medline CASGoogle Scholar
• 60. Gong QH, Cho JW, Huang T et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11(11), 357–368 (2001).
  Medline CASGoogle Scholar
• 61. Mackenzie PI, Bock KW, Burchell B et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 15(15), 677–685 (2005).
  Medline CASGoogle Scholar
• 62. Berg T, Hegelund Myrbäck T, Olsson M et al. Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects. Pharmacol Res Perspect. 2(4), e00054 (2014).
  MedlineGoogle Scholar
• 63. Runcharoen C, Fukunaga K, Sensorn I et al. Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). Hum. Genome Var. 8(1), 7 (2021).
  MedlineGoogle Scholar
• 64. Saigusa D, Matsukawa N, Hishinuma E, Koshiba S. Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics. Drug Metab. Pharmacokinet. 37, 100373 (2021).
  Medline CASGoogle Scholar
• 65. MacArthur DG, Tyler-Smith C. Loss-of-function variants in the genomes of healthy humans. Hum. Mol. Genet. 19(R2), R125–R130 (2010).
  Medline CASGoogle Scholar
• 66. MacArthur DG, Balasubramanian S, Frankish A et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335(6070), 823–828 (2012).
  Medline CASGoogle Scholar